This drug manufacturer has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Catalyst Pharmaceutical Partners currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include Lannett Company, Inc. (LCI), Questcor Pharmaceuticals, Inc. (QCOR) and Shire plc (SHPG). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Be the first to comment